Drug intelligence / Profile preview

Anshen Buxin Liuwei Pill

Development stage: Phase 4
Modality: Small Molecules
Administration: Oral

Overview

Anshen Buxin Liuwei Pill (ABLP) is a traditional Mongolian medicinal formula that has therapeutic effects on various cardiovascular conditions and psychological symptoms. It has been shown to protect against cardiac injury by suppressing cell necrosis/apoptosis, reducing excess oxidative stress, ameliorating mitochondrial membrane potential collapse, and reducing intracellular calcium concentration. Research indicates it can reverse H2O2-induced imbalance in the mRNA levels of calcium channel-related genes (DHPR, RyR2, SCN5A) and oxidative stress-related genes (Keap1, Nrf2, HO-1) in cardiac cells.

Brand names: 丹神
Other names: Anshen Buxin Liuwei PillABLP

Targets

CaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on Anshen Buxin Liuwei Pill.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anshen Buxin Liuwei Pill.

Explore the full profile